Evidence map›Paper›PMID 35547866›Full record

ArticleDrug design, development and therapy2022

Network Pharmacology Analysis of Hewei Jiangni Granule for Gastroesophageal Reflux Disease and Experimental Verification of Its Anti-Neurogenic Inflammation Mechanism.

Yuan Cheng, Fushun Kou, Xiaosi Zhang, Yi Dai, Lei Shi, Chune Xie, Xiaohong Li, Junxiang Li

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Yuan Cheng *Second Clinical Medical College, Beijing University of Chinese Medicine, Beijing, People's Republic of China.ORCID 0000-0003-1016-4060
Fushun Kou *Second Clinical Medical College, Beijing University of Chinese Medicine, Beijing, People's Republic of China.ORCID 0000-0003-1841-3324
Xiaosi ZhangSecond Clinical Medical College, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
Yi DaiDepartment of Pharmacotherapy and Oriental Medicine, School of Pharmacy, Hyogo University of Health Sciences, Hyogo, Japan.
Lei ShiDepartment of Gastroenterology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
Chune XieDepartment of Gastroenterology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
Xiaohong LiDepartment of Gastroenterology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
Junxiang LiDepartment of Gastroenterology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
Beijing University of Chinese Medicine · CNHyogo University of Health Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Proton pump inhibitors, as the first-line drugs for treating gastroesophageal reflux disease (GERD), are unable to completely relieve patients' symptoms and patients are prone to recurrence after prolonged drug withdrawal. Thus, it is crucial to find herbal medicines as a complementary and alternative treatment. Hewei Jiangni granule (HWJNG) is a classical Chinese medicinal formula with clinical therapeutic effects on GERD, but its pharmacological mechanism of action remains unclear. This study aimed to explore and then verify the pharmacological mechanisms of HWJNG in GERD therapy. Methods: A network pharmacology approach was applied to explore and then verify the pharmacological mechanisms of HWJNG in GERD therapy. The active ingredients of HWJNG, as well as therapeutic targets of GERD were acquired from specialized databases. The "herb-ingredient-gene-target" network for HWJNG in GERD treatment was built. The protein-protein interaction (PPI) network was constructed to screen the core coincident targets. Then, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. The core targets and signaling pathways associated with the anti-neurogenic inflammatory effect were partially verified via experiments in vivo at molecular level. Results: In total, 179 chemical ingredients in HWJNG and 298 intersection targets between GERD and HWJNG were selected from databases. A large proportion of core targets and top signaling pathways were involved in neurogenic inflammation. HWJNG significantly alleviated pathological injuries of esophagus and reversed dilated intracellular spaces. Additionally, HWJNG markedly inhibited the excessive release of inflammatory cytokines such as interleukin (IL)-1β, IL-6, tumor necrosis factor receptor (TNF-a), as well as regulated stimulation sensors including transient receptor potential vanilloid type 1 (TRPV1) and its related neuroinflammatory mediators in GERD mice. Conclusion: HWJNG is a promising therapeutic strategy for GERD treatment via regulation of multiple targets and pathways, its effects in alleviating neurogenic inflammation are especially acknowledged.

Indexed as

Drugs, Chinese HerbalGastroesophageal RefluxAnimalsAnti-Inflammatory AgentsHumansMedicine, Chinese TraditionalMiceMolecular Docking SimulationNetwork PharmacologyNeurogenic InflammationAnti-Inflammatory AgentsDrugs, Chinese Herbalgastroesophageal reflux diseaseHewei Jiangni granulenetwork pharmacologyneurogenic inflammation

Identifiers

PMID35547866
PMCPMC9084909
OpenAlexW4229081464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.